“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in USD
Last close As at 09/06/2023
USD1.32
▲ 0.04 (3.13%)
Market capitalisation
USD22m
Kazia Therapeutics’ lead asset paxalisib (a PI3K inhibitor that can cross the blood brain barrier (BBB), licensed from Genentech) is in a pivotal study for glioblastoma (GBM) and in early-stage studies in childhood brain cancers, DIPG and AT/RT. Phase I EVT801 is an inhibitor of VEGFR3.
GBM is the most common primary cancer of the brain with c 12,500–13,000 new cases reported in the United States per year. There are very limited treatment options for GBM and the survival rate is very low. Paxalisib is currently being developed for use in the adjuvant setting after initial resection and radiation treatment. EVT801 will target the multibillion-dollar angiogenesis cancer market.
Managing Director - Head of Content, Healthcare
Iain Ross
Chairman
John Friend
CEO
Karen Krumeich
CFO
Forecast net debt (US$m)
6
Forecast gearing ratio (%)
224
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | 7.1 | 28.2 | (77.5) |
| Relative | 3.2 | 19.1 | (78.4) |
| 52 week high/low | US$6.0/US$0.5 |
Kazia is developing the anti-cancer compound paxalisib (GDC-0084) for GBM and other brain cancers. Paxalisib is a PI3K inhibitor, with activity across a wide range of tumor types. Paxalisib, unlike other drugs of this class, can cross the BBB, opening the potential to treat cancers of the brain. Paxalisib has not progressed to stage 2 of the Phase III GBM AGILE study, although the first stage (~150 patients) remains ongoing, with final data expected in H2 CY23. A Phase II DIPG study (paxalisib in combination with ONC201) is also ongoing with initial data anticipated in CY23. In March 2023, Kazia announced a collaboration with the Australian and New Zealand Children’s Haematology/Oncology Group investigating paxalisib (with chemotherapy) in children with advanced solid tumors (Phase II). In May, CMO John Friend was appointed as the new CEO. The Q323-end cash balance was A$8m.
| Y/E Jun | Revenue (US$m) | EBITDA (US$m) | PBT (US$m) | EPS (fd) (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2021A | 10.7 | (3.1) | (3.1) | (25.09) | N/A | N/A |
| 2022A | 0.0 | (14.9) | (14.9) | (110.57) | N/A | N/A |
| 2023E | 0.0 | (19.0) | (19.0) | (111.41) | N/A | N/A |
| 2024E | 10.8 | (17.2) | (17.2) | (82.84) | N/A | N/A |
Get access to the very latest content matched to your personal investment style.
